Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rFXIII in mild to moderate active ulcerative colitis
NCT01706159Phase 2Terminated
- Sponsor
- Novo Nordisk
- Start
- Oct 2012
- Primary completion
- Jul 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
A Phase 2 trial of catridecacog in ulcerative colitis (UC), sponsored by Novo Nordisk. Started Oct 2012; status: terminated.
02
Drugs
catridecacog
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT01706159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01706159.